Sex: M
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Blood test, Computerised tomogram, Magnetic resonance imaging
Clinical narrative: began to recover his sense of smell and taste when he lost it again after the booster dose; began to recover his sense of smell and taste when he lost it again after the booster dose; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from medical information team. The reporter is the parent.  A 46-year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunization.  Relevant medical history included: "contracted covid", start date: Oct2020 (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose:1), administration date: Jan2021, for COVID-19 Immunization, reaction(s): "had a lost of taste and smell", "had a lost of taste and smell", "trembling inside his muscles", "electricity through his muscles"", "tingling in his hands and legs", "covid toes and fingers"; Bnt162b2 (Dose:2), administration date: Jan2021, for COVID-19 Immunization, reaction(s): "had a lost of taste and smell", "had a lost of taste and smell", "trembling inside his muscles", "electricity through his muscles"", "tingling in his hands and legs", "covid toes and fingers".  The following information was reported: ANOSMIA (non-serious), AGEUSIA (non-serious), outcome "not recovered" and all described as "began to recover his sense of smell and taste when he lost it again after the booster dose". The patient underwent the following laboratory tests and procedures: blood test: (2021) unknown; computerized tomogram: (2021) unknown; magnetic resonance imaging: (2021) unknown.  Additional Information: Questioned: Caller is a nurse, calling on behalf of her son. Caller's son is 46 years and is a schoolteacher. Caller's son contracted covid in Oct20 and received his Pfizer vaccines in Jan2021. Her son is also "boosted". Caller does not have LOT number available for son's boosters or specific dates of vaccines. Caller reported her son's case of covid is mild and he was "not hospitalized". Caller reported her son "has had continuing problems since having covid and the vaccines" and that he was scheduled to see a neurologist at # in a long covid clinic. Caller reported that her son has had a lost of taste and smell, "covid toes and fingers", tingling in his hands and legs, "trembling inside his muscles", "electricity through his muscles", he spent a night in the ER, had a "CAT scan" and a "MRI of his neck", and blood work. Caller stated that other teachers at her son school have reported a similar tingling sensation in hands and that all of the teachers were vaccinated the same day; the other teachers did not have covid. Caller adds that her son began to recover his sense of smell and taste when he lost it again after the booster dose. Caller adds that her son is trying to determine if he should get his 9-year old and 11 year old children vaccinated. Caller said they "don't know" if his symptoms are from "this vaccine or covid". Caller is seeking information on reports of numbness or tingling from the vaccine. E-transmitting with AE information. Caller declined to be transferred. Patient is male, 46 years. Responsed: Shared with caller that no reports of "numbness" or "tingling" were reported in the clinical trial data in the PI (LAB-1457-20.0; Revised: 03Jan2022). Safety response shared per attached VR. treatment disclaimer stated per attached VR. Referred to HCP. Referenced the attached "reports" document, noting that "spontaneous reports" of paresthesia have been reported but that specifics of those cases are not available at this time. Referred caller to the CDC and VAERS reporting site. Caller declined transfer; offered website. Assisted caller in navigating website for son's AE reporting. Fulfillment package offered; sent. Survey offered. Questioned: Caller said her son is trying to decide if he should vaccinate his children. Caller asked if there was different protein in the formulation for the children? Responsed: Shared with caller the orange cap formulation has been authorized for children 5-11 years of age per PI (LAB-1503-3.0; Revised: 03Jan2022). Shared with caller information from the attached document, that the difference between the purple cap and orange cap formulations is the buffer used which impacts storage. Questioned: Caller asked if there was a way to access reports filed about tingling and numbness. Caller commented that she "couldn't glean anything" from the material she read online, including the prescribing information, which is "why [I] called". Caller said she is wondering if there is any information on "accessing risks post study. Responsed: Shared with caller that accessing specific reports is not possible. Shared with caller that MI agent has searched through all available data and that there is no additional information at this time. Invited caller to contact Pfizer MI later to inquire if there is any additional data available. Questioned: Caller's husband said they are seeking "factual information to make a decision" and that "your company is making billions of dollars" and a some of that should go towards "organizing a better communication system". Caller's husband said that this is a "matter of facts", and it is "life-affecting". Caller also said it "bothers me", referring to the lack of information available. Responded: Recording disclaimer stated when caller's husband came on the phone. Acknowledge caller's and caller's husband's comments. Apologized for their experience and circumstances. Informed them their comments would be shared with the team.  No follow-up attempts are possible; No further information is expected.